Analyzing Enovis (ENOV) and Its Peers

Enovis (NYSE:ENOV) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it contrast to its peers? We will compare Enovis to similar companies based on the strength of its earnings, institutional ownership, valuation, dividends, risk, analyst recommendations and profitability.

Institutional & Insider Ownership

98.5% of Enovis shares are held by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 2.9% of Enovis shares are held by company insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Enovis and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Enovis	$2.25 billion	-$1.18 billion	-3.01
Enovis Competitors	$1.87 billion	$137.20 million	5.88

Enovis has higher revenue, but lower earnings than its peers. Enovis is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of current recommendations and price targets for Enovis and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enovis	1	1	10	0	2.75
Enovis Competitors	4295	10588	18373	832	2.46

Enovis currently has a consensus target price of $38.62, suggesting a potential upside of 39.22%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 21.04%. Given Enovis’ stronger consensus rating and higher probable upside, analysts plainly believe Enovis is more favorable than its peers.

Profitability

This table compares Enovis and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Enovis	-22.86%	13.23%	5.19%
Enovis Competitors	-303.57%	-175.14%	-22.20%

Volatility & Risk

Enovis has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Comparatively, Enovis’ peers have a beta of 2.68, meaning that their average share price is 168% more volatile than the S&P 500.

Summary

Enovis beats its peers on 8 of the 13 factors compared.

About Enovis

Enovis is a medical technology company that develops products and solutions for orthopedic care, surgery, recovery and rehabilitation. Its offerings include joint replacement implants, foot and ankle products, surgical instruments, orthopedic braces and supports, and rehabilitation equipment. The company serves healthcare providers and patients in markets around the world. Its products are designed to support treatment across different stages of musculoskeletal care, from surgical intervention to recovery and mobility.